Immunotherapies are expected to become a part of the standard preoperative and adjuvant treatment settings in various solid cancers. We saw continued momentum with new data presented at ESMO 2021 demonstrating the benefits of immunotherapy in early stage disease.

Click here to learn more: ESMO 2021